SELLAS Life Sciences Group, Inc. — Director's Dealing 2013

Feb 1, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2013-01-29

Reporting Person: Ahn Mark J (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-12-31	Common Stock, par value $0.0001	J	7668	$1.3	Acquired	100246	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-01-29	Stock Option (right to buy)	$1.71	A	650000	Acquired	2023-01-29	Common Stock (650000)	Direct

Footnotes

F1: Pursuant to the Issuer's Employee Stock Purchase Plan.

F2: Granted Pursuant to the Issuer's Amended and Restated 2007 Incentive Plan.

F3: Option vests in quarterly installments over four years beginning on the first quarterly anniversary of January 29, 2013, as long as Reporting Person remains continuously employed by the Issuer through such quarterly anniversary dates.